Научные статьи \ Прикладные науки. Медицина. Технология \ Mедицинские науки \ Патология. Клиническая медицина \ Нервная система. Невропатология. Неврология

Медуллобластома у детей. Клиника, диагностика, лечение, нерешенные проблемы

Медуллобластома у детей. Клиника, диагностика, лечение, нерешенные проблемы

Автор: Шонус Дарья Харлампиевна, Щербенко Олег Ильич

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 3 т.13, 2013 года.

Бесплатный доступ

В настоящем обзоре мы рассматриваем эпидемиологию, клинические проявления, диагностику и лечение медуллобластомы у детей. Особое внимание уделяется послеоперационной лучевой терапии в комбинации с химиотерапией, а также лечению медуллобластом у детей младшего возраста. Рассмотрены осложнения, возникающие при проведении химио-лучевого лечения медуллобластом у детей. Полученные данные при анализе литературы свидетельствуют о достаточно высокой вероятности достижения стойкой ремиссии у пациентов с локализованным процессом, но при распространенном процессе результаты лечения хуже. Таким образом, при лечении пациентов, входящих в высокую группу риска по возникновению метастазов медуллобластомы, требуется совершенствование методик лучевой и химиотерапии с возможным пересмотром используемых в настоящее время подходов в плане интенсификации воздействия на зоны риска рецидивирования опухоли. Совершенствование методов лечения должно базироваться на детальном анализе причин неудач и последствий используемых методов терапии.

Еще

Медуллобластома, диагностика, лучевая терапия, химиотерапия, осложнения

Короткий адрес: https://sciup.org/14955407

IDR: 14955407

Medulloblastoma in children. Clinical manifestations, diagnostics, treatment, the unsolved prolems

In the present literature review we consider epidemiology, clinical manifestations, diagnostics and treatment of medulloblastoma in children. The special attention in this review is paid to postoperative radiation therapy in a combination with chemotherapy and also to treatment of medulloblastoma in children of early age. The complications of chemotherapy and radiation therapy of medulloblastoma are considered. The data of the literature demonstrate rather high probability of achievement of permanent remission in patients with the localized tumor, but in metastatic disease the results of treatment are worse. Thus, in the high risk group the improvement of radio- and chemotherapy techniques is necessary with possible revision of treatment approaches to the possible zones of relapses. Improvement of methods of treatment should be based on the detailed analysis of treatment failures and late effects of the methods of therapy.

Еще

Список литературы Медуллобластома у детей. Клиника, диагностика, лечение, нерешенные проблемы

  • Артарян А.А. Опухоли мозжечка у детей.//Москва, Медицина, 1979, с. 175.
  • Гальперин Э.К., Констайн Л.С., Тарбел Н.Д. и др. Лучевая терапия в детской онкологии.//Москва. Медицина, 1999, с. 748.
  • Голдобенко Г.В., Дурнов Л.А., Шароев Т.А. Руководство по детской онкологии.//Москва. Миклош, 2003, с. 504.
  • Желудкова О.Г., Бородина И.Д., Русанова М.Г., и др. Результаты комплексного лечения медуллобластом у детей старше 3-х лет высокой группы риска по протоколу М-2000. Тезисы/доклад, Материалы Первой Всероссийской Конференции по детской нейрохирургии, Москва, 18-20 июня 2003 г., с.37.
  • Желудкова О.Г., Бухны А.Ф., Лившиц М.И. Результаты комплексного лечения медуллобластом у детей с использованием ПХТ и лучевой терапии. Ступино, 7-9 декабря 1999 года, Материалы Российского конгресса "Новые технологии в неврологии и нейрохирургии на рубеже тысячелетий", с. 65.
  • Желудкова О.Г., Коршунов А.Г., Горбатых СВ. и др. Злокачественные тератоидрабдоидные опухоли центральной нервной системы у детей.//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2003. т 2, № 4, с. 32-39.
  • Желудкова О.Г. Практическое руководство по детским болезням. Гематология/онкология детского возраста под редакцией Румянцева А.Г., Самочатовой Е.В. МЕДПРАКТИКА-М, Москва 2004, т. 4., с.653-657.
  • Коршунов А.Г., Сычева А.В., Голанов А.В. Иммуногистохимическое изучение экспрессии онокассоциированых белков в медуллобластомах мозжечка.//Вопросы нейрохирургии. 1998. № 4. с. 8-13.
  • Личиницер М., Кирсанов А. Применение противорвотных препаратов при химиотерапии злокачественных опухолей.//Москва. 1996. Европейская школа по онкологии. Сб. «Поддерживающая терапия у онкологических больных».
  • Мацко Д.Е., Коршунов А.Г. Атлас опухолей центральной нервной системы.//СПб. 1998. с. 76-80.
  • Переводчикова Н.И. Противоопухолевая химиотерапия. Справочник.//Москва. 2003. с. 221.
  • Холодов Б.В., Бухны А.Ф., Желудкова О.Г. и др. Роль химиотерапии в комплексном лечении опухолей головного мозга у детей.//Педиатрия. 1995. № 2. с. 91.
  • Хухлаева Е.А., Раевская С.А., Комаров В.И. и др. Злокачественные опухоли головы и шеи.//Медицина, Москва, 1993, с. 45.
  • Черствый Е.Д., Кравцова Г.И., Фурманчук А.В. Опухоли и опухолеподобные процессы у детей.//«Асар», Минск, 2002, с. 81-125.
  • Щербенко О.И., Говорина Е.В. Радиационные повреждения головного мозга после лучевой терапии опухолей ЦНС.//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2003, т.2, № 3, с.40-43
  • Albright A.L., Wisoff J.H., Zeltzer P.M. et al. Effects of medulloblastoma resections on outcome in children: a report from the Children's cancer Group.//Neurosurgery. 1996. V. 38. P. 265-271.
  • Aldosari N., Bigner S.H., Burger P.C. et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.//Arch Pathol Lab Med. 2002. V. 126. P. 540-544.
  • Allen J.C. Complications of chemotherapy in patients with brain and spinal cord tumors. Pedi-atr-Neurosurg. 1991-92, V. 17. N 4. P. 218-224.
  • Allen J.C., Donahue В., Da Rosso R., Nierenberg A. Hypofractionated craniospinal radiotherapy and adjuvant chemotherapy for children with primitive neuroectodermal tumors.//Int J Radiat Oncol Biol Phys. 1996. V. 30. P. 1155-61.
  • Bailey C., Gnekow A., Wellek S. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma: SIOP and GPO-SIOPII.//Med Pediatr Oncol. 1995. V. 25. P. 166-178.
  • Balis F. Concepts and physiological underpinnings of intrathecal chemotherapy. SIOP Abstract Book, 40 th Congress of the SIOP, Berlin, Germany, October 2-6. 2008. S.063. P. 13.
  • Bannering В., Rutkowski S., Gustafsson G. et al. HIT-SIOP PNET 4 multicentre study of hyperfractionated versus conventional RT in standard risk medulloblastoma.//SIOP Abstract Book, 40 th Congress of the SIOP, Berlin, Germany. October 2-6. 2008. O. 098. P. 45-46.
  • Bayani J., Zielenska M., Marrano P. et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping.//J Neurosurg. 2000. V. 93. P. 437-448.
  • Becker L.E., Giangaspero F., Rorke L.B. et al. Embryonal tumours. In: Kleihues P., Cavenee W.K., eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press, 2000. P. 123-148.
  • Bergman M., Pietsch T., Herms J. Medulloblastoma: a histological, immunohistochemical, ultrastructural and molecular genetic study.//Acta Neuropathologica, 1998, Abstract V. 95 Issue 2, P. 205212.
  • Biegel J.A., Janss A.J., Raffel С. et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system.//Clin Cancer Res 1997. V. 3. P. 473-478.
  • Biegel J.A. Cytogenetics and molecular genetics of childhood brain tumors.//Neurooncol. 1999. V. 1. P. 139-151.
  • Bilsky M.H., Lis E. The diagnosis and treatment of metastatic spinal tumor.//The Oncologist. 1999. V. 4. P. 456-469.
  • Blaney S.M., Poplack D.G. New cytotoxic drugs for intrathecal administration.//J Neuro-Oncol. 1998. V. 38. P. 219-23.
  • Borgwardt L., Hojgaard L., Carstensen H. et al. Increased fluorine-18 2-fluoro-2-deoxy-d-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG
  • positron emission tomography/magnetic resonance imaging coregistration and image fusion.//J Clin Oncol. 2005. V. 23. P. 3030-3037.
  • Bouffet E., Gentet J.C., Chastagner P. et al. High dose chemotherapy with autologous bone marrow rescue in childhood brain gliomas and ependimomas: an EBMT report. SIOP XXV Meeting. 1993. P. 563.
  • Bourne J.P., Geyer R., Berger M., et al. The prognostic significance of postoperative residual enhancement on CT scan in pediatric patients with medulloblastoma.//J Neuro-Oncol. 1992. V. 14. P. 263-70.
  • Brown H.G., Kepner J.L., Perlman E.J. et al: "Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group Study.//J Neuropathol Exp Neurol. 2000. V. 59. P. 857-865.
  • Carlos A., Luther W. “Principles and practice of radiation oncology”. J.B. Lippincott, Philadelphia. 1992. P. 1544.
  • Carrie C., Alapetite C., Mere P. et al. Quality control of radiotherapyeutic treatment of medulloblastoma in a multicentric study: the contribution of radiotherapy technique to tumor relapse. The French Medulloblastoma Group.//Radiother Oncol. 1992. V. 24. P. 77-81.
  • Carrie C., Hoffsteller S., Gomes F. et al. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP).//Int J Radiat Oncol Biol Phys. 1999. V. 45. P. 435-9.
  • Catsman-Berrevoets C.E., Van Donegan H.R., Mulder P.G. et al. Tumour type and size are high risk factors for the syndrome of "cerebellar" mutism and subsequent dysarthria.//J Neurol Neurosurg Psychiatry. 1999. V. 67. P. 755-757.
  • Cefalo G., Gandola L., Luksch R. Adjuvant high-dose sequential chemotherapy plus hyperfractionated radiotherapy in childhood medulloblastoma. SIOP-ASPH/O MEETING, Canada, Montreal, 1318 Sept, 1999, Abst., P. 31, 204.
  • Central Brain Tumors Registry of the United States (CBTRUS) Statistical report 2004-2005, www.cbtrus.org
  • Chan K.W., Fryer C.J., Steinbok P. Modification of the 8 drugs in 1 day regimen.//J Neurooncol. 1990. Oct; V. 9; N 2: P. 153-7.
  • Chang C.H., Housepian E.M., Herbert C. An operative system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas.//Radiology. 1969. V. 93. P. 1351-9.
  • Chi S.N., Gardner S.L., Levy A.S. et al. Feasibility and Response to Induction Chemotherapy In tensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma.//J. Clin Oncol. 2004. V. 22. P. 4881-4887
  • Christensen V., McDonough J., Tochner Z. Proton beam irradiation in pediatric oncology an overview.//J Ped Hematol Oncol. 2005. V27; N8: P. 444-448.
  • Clerico A., Cappelli С Schiavetti A. Adjuvant chemotherapy in medulloblastoma patients:
  • single institution experience. SIOP-ASPH/O MEETING, Canada, Monreal, 13-18 Sept, 1999, Abs., P. 32, 204.
  • Cochrane D.D., Gustavsson B., Poskitt K.P. et al. The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood.//Pediatr Neurosurg 1994; V. 20. P. 19-29
  • Cohen M.S., Duffner P. "Brain tumors in children. Principles of diagnosis and treatment" Raven Press New York, 1994.
  • Cohen В., Zeltzer P., Boyett J. et al. Prognostic factors and treatment results for primitive neuroectodermal tumors in children using radiation and chemotherapy: a Children's Cancer Group Randomized Trial.//J Clin Oncol 1996. V. 13. P. 1687-96.
  • Crofton P., Ahmed S., Wade J. et al. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.//J Clin Endocrinol Metab. 1998. V. 83. P. 3121-9.
  • Deutch M., Thomas P.R.M., Krischer J. Results of a prospective randomized trial comparing standart dose neuraxis irradiation (3,600 cGy/20) with redused neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A combined Childrens Cancer Group-Pediatric Oncology Group Study.//Pediatr Neurosurg. 1996. V. 24. P. 167-177.
  • Deutsch M. Medulloblastoma: staging and treatment outcome.//Int J Radiat Oncol Biol Phys. 1988;14:1103-1107.
  • Fouladi M., Heideman R., Langston J.W. et al. Infectious meningitis mimicking recurrent medulloblastoma on magnetic resonance imaging.//J Neurosurg. 1999. V. 91. P. 499-502.
  • Dieckmann K., Kren G., Schuller E. et al. Fractionated Stereotactic radiotherapy of residual or recurrent brain tumors in children after conventional radiotherapy. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999, Abstract, SL-54,P. 188.
  • Duffner P.K., Cohen M.E. Long-term consequences of CNS treatment for childhood cancer, Part II: Clinical Consequences.//Pediatr-Neurol. 1991. V. 7. N. 4. P. 237-42.
  • Duffner P.K., Horowitz M.E., Krischer J.P. et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.//N Engl J Med. 1993. V. 328. P. 1725-1731.
  • Duffner P.K., Horowitz M.E., Krischer J.P. et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience.//J Neuro-Oncol. 1999. V. 1. P. 152-61.
  • Duffner P.K., Krischer J.P., Horowitz M.E., et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group Study.//Ann Neurol. 1998. V. 44. P. 313-316.
  • Dunkel I.J., Boyett J.M., Yates A. et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group.//J
  • Clin Oncol. 1998. V. 16. P. 222-228.
  • Dupus-Girod S., Hartman O., Benhamon E. et al. Will high-dose chemotherapy followed by autologus bone marrow transplantation supplant craniospinal irradiation in young children treated for medulloblastoma.//J Neurooncol. 1996. V. 27. P. 87-98.
  • Eberhart C.G., Kratz J.E., Schuster A. et al: Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas.//Brain Pathol. 2002. V. 12. P. 36-44.
  • Ellison D.: Classifying the medulloblastoma: Insights from morphology and molecular genetics.//Neuropathol Appl Neurobiol. 2002. V. 28. P. 257-282.
  • Ellison D.W., Clifford S.C., Gajjar A., et al: What's new in neuro-oncology? Recent advances in medulloblastoma.//Eur J Paediatr Neurol. 2003. V. 7. P. 53-66.
  • Evans A.E., Jenkin R.D.T., Sposto R. et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine and prednisone.//J Neurosurg. 1990. V. 72. P. 572-82.
  • Ferencz T., Csaki Cs. Combined adjuvant chemotherapy in malignant pediatric brain tumors -preliminary results.//Medical and Pediatric Oncology. November 1997. V. 29. N5, Abstr. P. 113, 416.
  • Flores L.E., Williams D.L., Bell A.B. et al. Delay in the diagnosis of pediatric brain tumors.//Am J Child. 1986. V. 140. P. 684-686.
  • Fouladi M. et al. A Phase I., molecular biology and phase II study lapatinib (GW572016) in pediatric patients with recurrent or refractory medulloblastoma, malignant glioma or ependymoma. PBTC-016, 10/11/2004.
  • Fruhwald M.C., O'Dorisio M.S., Dai Z. et al. Aberrant hypermethylation of the major breakpoint cluster region in 17p 11.2 in medulloblastomas but not supratentorial PNETs.//Genes Chromosomes Cancer. 2001. V. 30. P. 38-47.
  • Gajjar A., Fouladi M., Walter A. Comparison of lumbar and shunt CFS for cytologyc detection of leptomeningeal disease in pediatric patients with brain tumors.//J Clin Oncol. 1999. V. 17. N6. P. 1825-1828.
  • Gajjar A. Recent advances in therapy for medulloblastoma. U.S.A., ASCO//J Clin Оncol. 1999. P. 579-586.
  • Gajjar A., Hernan R., Kocak M. Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma.//J Clin Oncol. 2004. V. 22. P. 984-993.
  • Gentet J.C., Bouffet E., Doz F. et al. Preirradiation chemotherapy including "eight drugs in one day" regimen and high-dose metotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.//J Neurosurg. 1995. V. 82. P. 608-614.
  • Geyer J.R., Zeltzer P.M., Boyett J.M. et al. Survival of infants with primitive Neuroectodermal
  • tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Children's Cancer Group.//J Clin Oncol. 1994. V. 12. P. 1607-15.
  • Geyer R., Jennings M., Boyett J. et al. Chemotherapy in infants with malignants brain tumors. ASCO. 1998. Abstr. P. 2019
  • Giangaspero F., Chieco P., Ceccarelli C. et al. "Desmoplastic" versus "classic" medulloblastoma: comparison of DNA content, histopathology and differentiation.//Virchows Arch A Pathol Anat Histopathol. 1991. V. 418. P. 207-214.
  • Gilbertson R. Paediatric embryonic brain tumours: Biological and clinical relevance of molecular genetic abnormalities.//Eur J Cancer. 2002. V. 38. P. 675-685.
  • Gilbertson R.J., Clifford S.C., MacMeekin W. et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implifications for the biology of medulloblastoma.//Cancer Res. 1998. V. 58. P. 3932-41.
  • Gilbertson R.J., Pearson A.D., Perry R.H. et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.//Br J Cancer. 1995. V. 71. P. 473-477.
  • Gilbertson R.J., Wickramasignghe C., Herman R. et al. Clinical and molecular stratification of disease risk in medulloblastoma.//Br J Cancer. 2001. V. 85. P. 705-712.
  • Giller C., Berger В., Pistenmaa D. et al. Robotically guided radiosurgery for children.//Ped Blood Cancer. 2005. V. 45. P. 304-310.
  • Glauser T.A., Packer R.J. Cognitive deficits in long term survivors of childhood brain tumors. U.S.A.//Child's Nervous System. 1991. V. 7. P. 2-12.
  • Gnekow A. Reccomendations of the Brain Tumor Subcommittee for the reporting of the trials. SIOP Brain Tumor Subcommittee. International Society of Pediatric Oncology.//Med Pediatr Oncol. 1995. V. 24. P. 104-108.
  • Gold D.R., Packer R.J., Cohen B.H. et al. Treatment strategies for medulloblastoma and primitive neuroectodermal tumors.//Neurosurg Focus, 1999, V7(2): e1.
  • Golomb L., Johnson J., Dunkel I., Halpern S. Chemotherapy only for young children with newly diagnosed malignant brain tumors: an update on the "Head Start" regimen. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999. Abstract. P. 18, 201.
  • Grotzer M.A., Hogarty M.D., Janss A.J. et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.//Clin Cancer Res. 2001. V. 7. P. 2425-2433.
  • Grotzer M.A., Janss A.J., Fung К. et al. TrkC expression Hinkes B.G., von Hoff K., Deinlein F., Warmuth-Metz M., et al. Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91.//J Neurooncol. 2007. V. 81. P. 217-223
  • Hart M.N., Early K.M. Primitive neuroectodermal tumors of the brain in children.//Cancer 1973. V. 32. P. 890-897.
  • Heideman R.L., Packer R.J., Albright L.A. et al. Tumors of the Central Nervous System. U.S.A. 1987. P. 505-547.
  • Herms J., Neidt I., Luscher B. et al: C-MYC expression in medulloblastoma and its prognostic value.//Int J Cancer 2000.V. 89. P. 395-402.
  • Hinkes B.G., von Hoff K., Deinlein F., Warmuth-Metz M. et al. Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91.//J Neurooncol. 2007. V. 81. P. 217-223.
  • Hong T.S., Mehta M.P., Boyett J.M. et al. Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a phase III combined modality study.//Ped Boold Cancer. 2005. V. 45. P. 676-682.
  • Howell R.M., Giebel A., Koontz-Raisig W. et all Comparison of therapeutic dosimetric data from passivly scattered proton and photon craniospinal irradition for medulloblastoma.//Radiat oncol. 2012. V. 24. N.7. P. 116.
  • Hyder D.J., Butturini A.M., Anderson C.P. High dose chemotherapy and autologous stem cell transplant for pediatric malignant brain tumors. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999, Abstract, P.19, 201.
  • Ilveskoski I., Saarinen U.M., Wiklund T. Growth impairment and growth hormone therapy in children treated for malignant brain tumors.//European Journal of Pediatrics, 1997. Abstract. V. 156 I10, P. 764-769.
  • Jakacki R., Schramm C., Donahue В. et al. Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniospinal irradiation.//J Clin Oncol. 1995. V. 13. P. 1478-1485.
  • Jakacki R., Zeltzer P., Boyett J., Albright L. et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Children's Cancer Group.//J Clin Oncol. 1995. V. 13. P. 1377-83.
  • Jenkin D., Shabanah M. Al, Shail E. Al, et al. Medulloblastoma. Prognostic factors. SIOPASPH/O MEETING, Canada, Monreal, 13-18 Sept, 1999, Abstract, V. 27. P. 279.
  • Jenkin D.K., Goddard D., Armstrong L. et al. Posterior fossa medulloblastoma in childhood: treatment results and a proposal for a new staging system.//Int J Radiat Oncol Biol Phys. 1990. V. 19. P. 265-74.
  • Johnston D., Daniel L., Keene L., Lafay-Cousin L. Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report.//J Neurooncol. 2007. DOI 10.1007/sl 1060 007-9440-1.
  • Jones B., Wilson P., Nagano A. et all. Dillemas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma.//Br J Radiol. 2012 Oct: 85 (1018): t 912-8.
  • Kalapurakal J.A., Goldman S., Hsieh Y.С. Long term results of hyper fractionated craniospinal
  • radiation in medulloblastoma.//SIOP-ASPH/O MEETING, Canada, Monreal, 13-18 Sept, 1999, Abstract, P. 52, 208.
  • Kalifa C., Grill J. The therapy of infantile malignant brain tumors: current status.//J Neuro-Oncol. 2005. V. 75. P. 279-285.
  • Khong P., Leung L., Fung A. et al. White matter anisotropy in post-treatment childhood cancer survivors: preliminary evidence of association with neurocognitive function.//J Clin Oncol. 2006. V. 24. P. 884-890.
  • Kieffer-Renaux V., Viguier D., Raqune M.A. et al. Therapeutic schedueles influence the pattern of intellectual decline after irradiation of posterior fossa tumors.//Ped Blood Cancer. 2005. V. 45. P. 814-819.
  • Kim J.Y., Sutton M.E., Lu D.J. et al. Activation of neurotrophin-3 receptor TrkC induces apop-tosis in medulloblastomas.//Cancer Res. 1999. V. 59. P. 711-719.
  • Kortmann R.D., Kuhl J., Timmermann В. et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.//Int J Radiat Oncol Biol Phys. 2000. V. 46. P. 269-279
  • Krischer J.P., Ragab A., Kun L. et al. Nitrogen mustard, vincristine, procarbazine and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma.//J Neurosurg. 1991. N. 74. P. 905 9.
  • Kuhl J., Bode U., Deinlein F., Ottensmeier H. Cure of infants with medulloblastoma (МО/MI stage) by postoperative chemotherapy only.//SIOP-ASPH/O MEETING, Canada, Monreal, 13-18 Sept, 1999, Abstract, P107, 169.
  • Kuhl J., Doz F., Taylor R. Embryonic tumors. Walker D.A., Perilongo G., Punt J.A.G., Taylor R.E., eds. Brain and spinal Tumors of childhood.//Arnold, New York. 2004: P. 314-330, 436.
  • Kuhl J., Muller H.L., Berthold F. et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German Pilot trial HIT'88/89.//Klin Padiatr. 1998. Jul-Aug. V. 210. N. 4. P. 227-33.
  • Kuhl J., Gnekow A., Havers W. et al. Primary chemotherapy after surgery and delayed irradia tion in children under three years of age with medulloblastoma -pilot trial of the German Pediatric Brain Tumor Study Group. Protocol HIT-91, 1991.
  • Kumar R., Achari G., Banerjee D. et al. Uncommon presentation of medulloblastoma.//Childs Nerv Syst. 2001; N. 17: P. 538-542; discussion 543
  • Kun L.E. Brain tumors in infants and young children. U.S.A, ASCO.//J Clin Oncol. 1999. P. 574-578.
  • Laurent J.P., Chang C.H., Cohen M.E. A classification system for primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa.//Cancer. 1985. V. 56 (7 Suppl). P. 1807-1809.
  • Lee M., Wisoff J.H., Abbott R. et al. Management of hydrocephalus in children with medulloblastoma: prognostic factors for shunting.//Pediatr Neurosurg. 1994. V. 2: P. 240-247.
  • Louis D., Cavenee W., Ohgaki H. World Health Organization classification of tumors of the central nervous system. 4lh Edition. Lyon, France: International Agency for Research on Cancer. 2007. P. 8-11, 132-149.
  • MacDonald T.J., Brown K.M., LaFleur В. et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease.//Nat Genet. 2001. V. 29: P. 143-152
  • Marymont M.R., Geohas J., Tomita Т. et al. Hyperfractionated craniospinal radiation in medulloblastoma.//Pediatr Neurosurg. 1996; V. 24: P. 178-84.
  • Meyers C.A., Brown P. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors.//J of Clin Oncol. 2006. V. 24. N8. P. 1305-9.
  • Michalski J. et al. A Study evaluating limited target volume boost irradiation and reduced dose craniospinal radiotherapy (18,0 Gy) and chemotherapy in children with newly diagnosed standard risk medulloblastoma: a Phase III double randomized trial. 09/10/04, P. 1-92.
  • Milde Т., Oehme I., Pfiser S. et al. Histone deacetylases 5 and 9 are novel markers for medulloblastoma risk stratification and potential drug targets for therapy. SIOP Abstract Book, 40 th Congress of the SIOP, Berlin, Germany. October 2-6. 2008. O.096. P. 45.
  • Mirabell R., Bieri S. Medulloblastoma staging: is the cerebrospinal fluid cytology a reliable prognostic factor.//Medical and Pediatric Oncology. November 1997. V. 29. N. 5. Abstr. P. 61, 401.
  • Mirabell R., Bieri S., Huguenin P. et al. Prognostic value of cerebrospinal fluid cytology in pediatric medulloblastoma. Swiss Pediatric Oncology Group.//Ann Oncol. 1999. V. 10. P. 239-41.
  • Mosijczuk A.D., Nigra M.A., Thomas P.R.M. et al. Pre-irradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group Pilot Study.//Cancer. 1993. V. 72. P. 2755-62.
  • Mulherm R.K., Reddick W.E., Elkin T.D. Neurocognitive deficits in medulloblastoma survivors are associated with white matter loss.//Medical and Pediatric Oncology. November 1997. V. 29. N. 5. Abstr. P. 173, 365.
  • Norris L.S., Snodgrass S., Miller D.C. et al. Recurrent central nervous system medulloepithelioma: response and outcome following marrow-ablative chemotherapy with stem cell rescue.//J Pediatr Hematol Oncol. 2005. V. 27. P. 264-266.
  • Ogilvy-Stuart A., Clayton P., Shalet S. Cranial irradiation and early puberty.//J Clin Endocrinol Metab. 1994. V. 78. P. 1282-6.
  • Oyharcabal-Bourden V., Kalifa C., Gentet J.C. et al. Standard risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French society of pediatric oncology study.//J Clin Oncol. 2005. V. 23. P. 4726-34.
  • Packer R. Brain tumors in children.//Arch Neurol. 1999.V. 56. P. 421-425.
  • Packer R., Boyett J., Janns A. et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control.//J Clin Oncol. 2001. V. 19. P. 480-7.
  • Packer R.J. Progress and challenges in childhood brain tumors.//J of Neuro-Oncol. 2005. V.75. P. 239-42.
  • Packer R.J., Goldwein J., Nicholson H.S. et al. Treatment of children with medulloblastoma with reduced dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study.//J Clin Oncol. 1999. V. 17. P. 2127-36.
  • Packer R.J., Sutton L.N., Elterman R. et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU and vincristine chemotherapy.//J Neurosurg. 1994.V. 81. P. 690-698.
  • Packer R.J., Cogen P., Vezina G. et al. Medulloblastoma: clinical and biologic aspects.//Neurooncol. 1999. V. 1. P. 232-250.
  • Paulino A.C., Wen B.C., Mayr N.A. et al. Protracted radiotherapy treatment duration in medulloblastoma.//Am J Clin Oncol. (CCT) 2003. V. 26. N. 1. P. 55-59.
  • Pietsch T. Molecular pathogenesis of embryonal tumors: loss of developmental control. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999, Abstract, SL-56, 188.
  • Pollack I.F., Polinko P., Albright A.L. et al. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology.//Neurosurgery. 1995. V. 37. P. 885-893.
  • Prados M.D., Edwards M.S., Chang S.M. et al. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a phase II study.//Int J Radiat Oncol Biol Phys. 1999. V. 43. P. 279-85.
  • Prityko A., Kholodov B., Geludkova O. Hematological toxicity of chemotherapy in children with medulloblastoma. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999, Abstract, P. 85, 294.
  • Probert J., Packer В., Kaplan H. Growth retardation in children after megavoltage irradiation of the spine.//Cancer. 1973. V. 32. P. 634-9.
  • Raffel C., Jenkins R.B., Frederick L. et al. Sporadic medulloblastomas contain PTCH mutations.//Cancer Res. 1997. V. 57. P. 842-845.
  • Reddy A.T., Janss A.J., Phillips P.C. et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation and chemotherapy.//Cancer. 2000. V. 88. P. 2189-2193.
  • Reddy A.T., Janss A.J., Phillips P.C. et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation and chemotherapy.//Cancer. 2000. V. 88. P. 2189-2193.
  • Ricardi U., Besenzon L., Cordero di Montezemolo L. et al. Low dose hyperfractionated craniospinal radiation therapy for childhood cerebellar medulloblastoma: Early results of phase I-II study.//European Journal of Cancer, 1997. Abstr. P. 911.
  • Rickert С.H. Abdominal metastases of pediatric brain tumors via ventriculo-peritoneal shunts.//Childs Nervous System. 1998. Abstract V. 14 I.1/2. P. 10-14.
  • Robinson G. Acute Neurologic dysfunction in Brain Tumor Patients undergoing autologous BMT. www.cure4kids.org 2008.
  • Rocco C.Di, Iarmelli A., Papacci F. et al. Prognosis of medulloblastoma in infants. Child's Nervous System. 1997. Abstract V. 13 I. 7. P. 388-396.
  • Roman D.D., Sperduto P.W. Neuropsychological effects of cranial radiation: current knowledge and future directions.//Int J Radiat Oncol Biol Phys. 1995. V. 31. P. 983-98.
  • Rorke L.B., Packer R.J., Biegel J.A. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity.//J Neurosurg. 1996. V. 85. P. 56-65.
  • Rutka J.T., Hoffman H.J. Medulloblastoma: a historical perspective and overview.//J Neuro-Oncol. 1996. V. 29. P. 1-7.
  • Rutkowski S. Chemotherapeutic strategies for young children with brain tumors. SIOP Abstract Book, 40 th Congress of the SIOP, Berlin, Germany, October 2-6, 2008. S.026. P. 7.
  • Saran F.H., Driever P.H., Thilmann С. et al. Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation.//Int J Radiat Oncol Biol Phys. 1998. V. 42. P. 959-967.
  • Scheurlen W., Schwabe G., Kuhl J. Molecular markers predicting poor outcome in medulloblastoma and supratentorial PNET.//Medical and Pediatric Oncology. November 1997. V. 29. N.5. Abstr. 0-4, 316.
  • Schmiegelow M., Lassen S., Poulsen H.S. Long lasting growth hormone deficiency (GHD) following radiotherapy of a brain tumor in childhood abrogates the response to growth hormone releasing hormone. SIOP-ASPH/O MEETING. Canada, Monreal. 13-18 Sept. 1999. Abstract. 0-75, 162.
  • Segal R.A., Goumnerova L.C., Kwon Y.K. et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma.//Proc Natl Acad Sci USA. 1994. V. 91. P. 12867-12871
  • Slampa P., Zitterbart K., Dusek L. et al. Craniospinal irradiation of medulloblastoma in the supine position.//Rep Pract Oncol Radiother. 2006. V. 11. N. 6. P. 265-272
  • Slave I., Schuller E., Czech T. et al. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.//J Neurooncol. 1998. V. 38. P. 213-218.
  • Smith M.A., Freidlin В., Ries L.A. et al. Trends in reported incidence of primary tumors in children in the United States. U.S.A.//J Nati Cancer Inst. 1998. V. 90. P. 1269-1277.
  • Stavrou Т., Nicholson H.S., Byrne J. et al. Genetic predisposition and second cancer in childhood medulloblastoma. ASCO. 1998. Abstr. 2166.
  • Strother D., Ashley D., Kellie S.J. et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem cell rescue for patients with newly diagnosed medulloblastoma or supratentorial PNET after craniospinal radiotherapy: results of a collaborative study.//J Clin Oncol. 2001. V. 19. N.10. P. 2696-2704.
  • Tait D.M., Thornton-Jones H., Bloom H.J.G., Lemerie J. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Pediatric Oncology (SIOP I),//Eur J Cancer. 1990. V. 26. P. 464-469.
  • Taylor R.E., Bailey C.C., Robinson K. et al. Results of randomized study of the preradiotherapy chemotherapy vs radiotherapy alone for non-metastatic (M0-1) medulloblastoma. The SIOP/UKCCSG PNET-3 study.//J Clin Oncol. 2003. V. 21. P. 1581-1591.
  • Thomas P.R., Deutsch M., Kepner J.L. et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuroaxis irradiation.//J Clin Oncol. 2000.V.18. P. 3004-3011.
  • Timmermann В., Kortmann R.D., Kuhl J. et al. Role of radiatiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT~SKK'87and HIT-SKK'92 trials.//J Clin oncol. 2006. V. 24. P. 1554-1560.
  • Tompson M., Fuller C., Hogg Т. et al. Genomic identifies medulloblastoma subgroups that are enriched for specific genetic alterations.//J Clin Oncol. 2006.V. 24. P. 1924-1931.
  • Uysal K.M., Sanalioglu F., Olgun N. Hemolitic anemia and capillary-leak syndrom in a patient with medulloblastoma who received carbo-platinum-based chemotherapy (SIOP/PNET III regimen).//Medical and Pediatric Oncology. November 1997. V. 29. N. 5. Abstr. 129, 490.
  • Wada C., Kurata A., Hirose R. et al. Primary leptomeningeal ependymoblastoma. Case report.//J Neurosurg. 1986. V. 64. P. 968-973.
  • Walker D.A., Perilongo G., Punt J.A.G., Taylor R.E. Brain and spinal Tumors of childhood. Arnold. New York. 2004. P. 324.
  • Walker R., Allen J., Rosen G. et al. Transient cerebral dysfunction secondary to high-dose methotrexate.//J Clin Oncol. 1986. V. 4. P. 1845-1850.
  • Watterson J., Simonton SC., Rorke L.B. et al. Fatal brain stem necrosis after standard posterior fosse radiation and aggressive chemotherapy for metastatic medulloblastoma.//Cancer. 1993. V. 71. N. 12. P. 4111-4117.
  • Wetmore C., Eberhart D.E., Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched.//Cancer Res. 2001. V. 61. P. 513-516.
  • Wisoff J.H., Epstein F.J. Pseudobulbar palsy after posterior fossa operation in children. U.S.A.//Neurosergery. 1984. V. 15. P. 707-709.
  • Xu W., Janss A., Packer R., Phillips P. et al. Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy.//Neuro-Oncol. 2004. V. 6. P. 113-118.
  • Yamada K., Yamashiro S., Itoyama Y. et al. Sinus thrombosis during CDDP and VP-16 (PE) therapy for suprasellar germ-cell tumor: case report.//No-Shinkei-Geka. 1993. V. 21. N. 11. P. 1025-9.
  • Yang Z.J. et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.//Cancer Cell. 2008. V. 14. P. 135-145.
  • Young S.W., Qing F., Harriman A. et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRJ.//Proc Natl Acad Sci USA. 1996. V. 93. P. 6610-6615.
Еще
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp